BFEC
LXRX icon

Benjamin F. Edwards & Company’s Lexicon Pharmaceuticals LXRX Stock Holding History

Benjamin F. Edwards & Company’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-150
Closed -$1K – 1651
2017
Q4 		$1K Hold
150
– – ﹤0.01% 1540
2017
Q3 		$2K Buy
+150
New +$2.21K ﹤0.01% 1452

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

Benjamin F. Edwards & Company's LXRX Position: Q1 2018 in Review

Benjamin F. Edwards & Company sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2018, closing a stake of 150 shares — an estimated $1K sold.

Benjamin F. Edwards & Company first reported a position in LXRX in Q3 2017 and held it in 2 quarters. The position peaked at $2K in Q3 2017. 126 funds tracked by Wall St. Rank hold LXRX as of Q1 2018.

  • Benjamin F. Edwards & Company reported no remaining Lexicon Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 150 Lexicon Pharmaceuticals shares in Q1 2018, an estimated $1K.
  • Benjamin F. Edwards & Company first reported a position in Lexicon Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • Benjamin F. Edwards & Company's Lexicon Pharmaceuticals position peaked at $2K in Q3 2017.
  • 126 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2018.

Based on Benjamin F. Edwards & Company's 13F filing for Q1 2018, filed 17 Apr 2018.